O ROURKE & COMPANY Inc boosted its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 6.9% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 6,867 shares of the company’s stock after purchasing an additional 442 shares during the period. O ROURKE & COMPANY Inc’s holdings in Merck & Co., Inc. were worth $780,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Itau Unibanco Holding S.A. acquired a new stake in Merck & Co., Inc. during the 2nd quarter worth $39,000. Abich Financial Wealth Management LLC boosted its position in Merck & Co., Inc. by 121.8% during the second quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock worth $40,000 after acquiring an additional 179 shares during the last quarter. Quarry LP acquired a new position in shares of Merck & Co., Inc. during the 2nd quarter valued at about $42,000. Strategic Financial Concepts LLC boosted its holdings in shares of Merck & Co., Inc. by 1,475.6% in the 2nd quarter. Strategic Financial Concepts LLC now owns 35,057 shares of the company’s stock valued at $43,000 after purchasing an additional 32,832 shares during the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC grew its position in Merck & Co., Inc. by 47.5% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 379 shares of the company’s stock valued at $43,000 after acquiring an additional 122 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on the company. Sanford C. Bernstein started coverage on Merck & Co., Inc. in a report on Thursday, October 17th. They issued a “market perform” rating and a $115.00 price target for the company. Barclays lowered their price target on Merck & Co., Inc. from $142.00 to $140.00 and set an “overweight” rating on the stock in a report on Monday, October 7th. Wells Fargo & Company decreased their price target on Merck & Co., Inc. from $140.00 to $125.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 31st. Citigroup lowered their price objective on shares of Merck & Co., Inc. from $140.00 to $130.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. Finally, Truist Financial decreased their target price on Merck & Co., Inc. from $143.00 to $132.00 and set a “buy” rating on the stock in a report on Wednesday, October 9th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, nine have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and an average price target of $131.46.
Merck & Co., Inc. Stock Down 3.3 %
Shares of NYSE:MRK traded down $3.50 during trading on Thursday, hitting $101.33. 7,705,437 shares of the company were exchanged, compared to its average volume of 8,808,198. The stock has a market cap of $256.65 billion, a price-to-earnings ratio of 18.89, a P/E/G ratio of 1.49 and a beta of 0.39. Merck & Co., Inc. has a fifty-two week low of $98.60 and a fifty-two week high of $134.63. The firm has a fifty day moving average price of $112.87 and a two-hundred day moving average price of $121.17. The company has a current ratio of 1.47, a quick ratio of 1.22 and a debt-to-equity ratio of 0.80.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its quarterly earnings data on Tuesday, July 30th. The company reported $2.28 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.12. Merck & Co., Inc. had a net margin of 21.99% and a return on equity of 40.69%. The company had revenue of $16.10 billion during the quarter, compared to the consensus estimate of $15.87 billion. During the same quarter last year, the firm posted ($2.06) EPS. The company’s quarterly revenue was up 7.1% on a year-over-year basis. As a group, research analysts anticipate that Merck & Co., Inc. will post 7.76 earnings per share for the current fiscal year.
Merck & Co., Inc. Profile
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
See Also
- Five stocks we like better than Merck & Co., Inc.
- What Are Trending Stocks? Trending Stocks Explained
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- What is the Nasdaq? Complete Overview with History
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.